| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| ELMDElectromed, Inc. | 239.29M | 28.69 | 33.36 | 16.97% | 12.38% | 18.32% | 4.63% | 0.00 |
| XAIRBeyond Air, Inc. | 7.02M | 0.88 | -0.06 | 219.67% | -6.32% | -280.24% | 0.82 | |
| LUNGPulmonx Corporation | 82.08M | 1.99 | -1.38 | 22.01% | -61.91% | -94.54% | 0.66 | |
| AVNSAvanos Medical, Inc. | 555.63M | 11.97 | -1.40 | 2.15% | -67% | -60.27% | 14.92% | 0.21 |
| INGNInogen, Inc. | 168.59M | 6.21 | -4.09 | 6.35% | -7.31% | -12.87% | 0.11 | |
| QIPTQuipt Home Medical Corp. | 156.3M | 3.55 | -14.79 | -0.23% | -4.11% | -10.06% | 16.21% | 0.16 |
| IINNInspira Technologies Oxy B.H.N. Ltd. | 34.51M | 0.96 | -1600 | -190.28% | 0.58 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 20M | 32.59M | 32.73M | 48.42M | 53.66M | 68.67M | 83.79M |
| Revenue Growth % | - | 0.63% | 0% | 0.48% | 0.11% | 0.28% | 0.22% |
| Cost of Goods Sold | 7.72M | 10.18M | 11.53M | 12.79M | 13.8M | 17.92M | 21.79M |
| COGS % of Revenue | 0.39% | 0.31% | 0.35% | 0.26% | 0.26% | 0.26% | 0.26% |
| Gross Profit | 12.29M | 22.41M | 21.2M | 35.63M | 39.87M | 50.75M | 62M |
| Gross Margin % | 0.61% | 0.69% | 0.65% | 0.74% | 0.74% | 0.74% | 0.74% |
| Gross Profit Growth % | - | 0.82% | -0.05% | 0.68% | 0.12% | 0.27% | 0.22% |
| Operating Expenses | 27.34M | 40.25M | 53.53M | 82.93M | 98.5M | 112.69M | 119.7M |
| OpEx % of Revenue | 1.37% | 1.23% | 1.64% | 1.71% | 1.84% | 1.64% | 1.43% |
| Selling, General & Admin | 20.35M | 34.2M | 46.07M | 69.87M | 83.11M | 94.61M | 102.14M |
| SG&A % of Revenue | 1.02% | 1.05% | 1.41% | 1.44% | 1.55% | 1.38% | 1.22% |
| Research & Development | 6.99M | 6.05M | 7.46M | 13.06M | 15.4M | 18.08M | 17.57M |
| R&D % of Revenue | 0.35% | 0.19% | 0.23% | 0.27% | 0.29% | 0.26% | 0.21% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -15.05M | -17.84M | -32.33M | -47.3M | -58.64M | -61.94M | -57.7M |
| Operating Margin % | -0.75% | -0.55% | -0.99% | -0.98% | -1.09% | -0.9% | -0.69% |
| Operating Income Growth % | - | -0.19% | -0.81% | -0.46% | -0.24% | -0.06% | 0.07% |
| EBITDA | -14.78M | -16.64M | -31.93M | -46.44M | -57.12M | -59.99M | -56.11M |
| EBITDA Margin % | -0.74% | -0.51% | -0.98% | -0.96% | -1.06% | -0.87% | -0.67% |
| EBITDA Growth % | - | -0.13% | -0.92% | -0.45% | -0.23% | -0.05% | 0.06% |
| D&A (Non-Cash Add-back) | 270K | 1.2M | 400K | 867K | 1.51M | 1.95M | 1.59M |
| EBIT | -15.95M | -18.02M | -28.84M | -47.49M | -57.5M | -57.04M | -52.39M |
| Net Interest Income | -2.5M | -1.89M | -2.97M | -429K | 463K | 2.34M | 1.55M |
| Interest Income | 21K | 432K | 213K | 400K | 1.53M | 5.57M | 5.06M |
| Interest Expense | 2.52M | 2.32M | 3.18M | 829K | 1.07M | 3.23M | 3.51M |
| Other Income/Expense | -3.42M | -2.5M | 314K | -1.01M | 67K | 1.66M | 1.81M |
| Pretax Income | -18.47M | -20.34M | -32.02M | -48.32M | -58.57M | -60.27M | -55.89M |
| Pretax Margin % | -0.92% | -0.62% | -0.98% | -1% | -1.09% | -0.88% | -0.67% |
| Income Tax | 12K | 363K | 213K | 343K | 353K | 571K | 500K |
| Effective Tax Rate % | 1% | 1.02% | 1.01% | 1.01% | 1.01% | 1.01% | 1.01% |
| Net Income | -18.48M | -20.7M | -32.23M | -48.66M | -58.92M | -60.84M | -56.39M |
| Net Margin % | -0.92% | -0.64% | -0.98% | -1.01% | -1.1% | -0.89% | -0.67% |
| Net Income Growth % | - | -0.12% | -0.56% | -0.51% | -0.21% | -0.03% | 0.07% |
| Net Income (Continuing) | -18.48M | -20.7M | -32.23M | -48.66M | -58.92M | -60.84M | -56.39M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.89 | -0.58 | -0.90 | -1.35 | -1.59 | -1.60 | -1.44 |
| EPS Growth % | - | 0.35% | -0.55% | -0.5% | -0.18% | -0.01% | 0.1% |
| EPS (Basic) | -0.89 | -0.58 | -0.90 | -1.35 | -1.59 | -1.60 | -1.44 |
| Diluted Shares Outstanding | 20.71M | 35.43M | 35.69M | 36.13M | 37.1M | 37.97M | 39.11M |
| Basic Shares Outstanding | 20.71M | 35.43M | 35.69M | 36.13M | 37.1M | 37.97M | 39.11M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 11.31M | 41.07M | 249.99M | 208M | 168.95M | 150.42M | 136.25M |
| Cash & Short-Term Investments | 4.12M | 28.35M | 231.79M | 180.04M | 141.14M | 117.1M | 101.48M |
| Cash Only | 4.12M | 14.77M | 231.79M | 148.48M | 101.74M | 83.55M | 70.91M |
| Short-Term Investments | 0 | 13.58M | 0 | 31.56M | 39.4M | 33.55M | 30.58M |
| Accounts Receivable | 3.42M | 6M | 4.57M | 6.92M | 9.28M | 13.02M | 13.79M |
| Days Sales Outstanding | 62.42 | 67.17 | 50.93 | 52.2 | 63.11 | 69.2 | 60.08 |
| Inventory | 3.32M | 5.61M | 10.74M | 16.29M | 14.56M | 16.74M | 16.91M |
| Days Inventory Outstanding | 157.01 | 201.2 | 339.99 | 464.89 | 385.29 | 340.97 | 283.37 |
| Other Current Assets | 125K | 666K | 377K | 578K | 521K | 741K | 1.39M |
| Total Non-Current Assets | 3.71M | 12.46M | 13.72M | 27.17M | 24.72M | 27.36M | 26.6M |
| Property, Plant & Equipment | 375K | 7.46M | 10.45M | 12.89M | 10.5M | 7.43M | 21.45M |
| Fixed Asset Turnover | 53.34x | 4.37x | 3.13x | 3.76x | 5.11x | 9.24x | 3.91x |
| Goodwill | 2.33M | 2.33M | 2.33M | 2.33M | 2.33M | 2.33M | 2.33M |
| Intangible Assets | 647K | 524K | 400K | 277K | 154K | 31K | 0 |
| Long-Term Investments | 0 | 0 | 0 | 10.94M | 5.92M | 14.39M | 0 |
| Other Non-Current Assets | 350K | 2.14M | 536K | 731K | 5.81M | 3.17M | 2.82M |
| Total Assets | 15.01M | 53.53M | 263.71M | 235.17M | 193.68M | 177.78M | 162.85M |
| Asset Turnover | 1.33x | 0.61x | 0.12x | 0.21x | 0.28x | 0.39x | 0.51x |
| Asset Growth % | - | 2.57% | 3.93% | -0.11% | -0.18% | -0.08% | -0.08% |
| Total Current Liabilities | 8.07M | 14.16M | 12.53M | 17.55M | 18.49M | 23.16M | 24.44M |
| Accounts Payable | 1.29M | 2.68M | 1.47M | 1.58M | 1.76M | 1.5M | 3.83M |
| Days Payables Outstanding | 60.96 | 96.12 | 46.59 | 45.16 | 46.51 | 30.49 | 64.11 |
| Short-Term Debt | 0 | 0 | 2.24M | 91K | 90K | 2.15M | 3.18M |
| Deferred Revenue (Current) | 139K | 173K | 71K | 163K | 120K | 104K | 135K |
| Other Current Liabilities | 2.49M | 6.47M | 3.1M | 4.74M | 4.97M | 7.88M | 6.89M |
| Current Ratio | 1.40x | 2.90x | 19.96x | 11.85x | 9.14x | 6.50x | 5.58x |
| Quick Ratio | 0.99x | 2.50x | 19.10x | 10.92x | 8.35x | 5.77x | 4.88x |
| Cash Conversion Cycle | 158.47 | 172.25 | 344.32 | 471.92 | 401.9 | 379.68 | 279.33 |
| Total Non-Current Liabilities | 174.27M | 226.75M | 25.05M | 24.38M | 21.18M | 36.31M | 52.6M |
| Long-Term Debt | 33.6M | 220.3M | 17.37M | 17.32M | 17.23M | 35.09M | 34M |
| Capital Lease Obligations | 0 | 6.4M | 7.62M | 6.84M | 3.85M | 1.11M | 18.52M |
| Deferred Tax Liabilities | 48K | 43K | 62K | 37K | 94K | 114K | 87K |
| Other Non-Current Liabilities | 140.61M | 0 | 0 | 179K | 0 | 0 | 0 |
| Total Liabilities | 182.34M | 240.91M | 37.57M | 41.93M | 39.67M | 59.47M | 77.04M |
| Total Debt | 33.6M | 227.15M | 27.22M | 26.46M | 24.4M | 41.42M | 56.47M |
| Net Debt | 29.48M | 212.39M | -204.57M | -122.02M | -77.33M | -42.12M | -14.43M |
| Debt / Equity | - | - | 0.12x | 0.14x | 0.16x | 0.35x | 0.66x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -5.97x | -7.70x | -10.16x | -57.06x | -55.01x | -19.16x | -16.45x |
| Total Equity | -167.33M | -187.38M | 226.13M | 193.24M | 154.01M | 118.31M | 85.81M |
| Equity Growth % | - | -0.12% | 2.21% | -0.15% | -0.2% | -0.23% | -0.27% |
| Book Value per Share | -8.08 | -5.29 | 6.34 | 5.35 | 4.15 | 3.12 | 2.19 |
| Total Shareholders' Equity | -167.33M | -187.38M | 226.13M | 193.24M | 154.01M | 118.31M | 85.81M |
| Common Stock | 17K | 19K | 36K | 37K | 38K | 39K | 40K |
| Retained Earnings | -189.8M | -210.5M | -242.73M | -291.39M | -350.32M | -411.16M | -467.56M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 1.33M | 1.37M | 1.69M | 1.71M | 1.57M | 2.64M | 2.11M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -18.39M | -20.77M | -30.63M | -41.43M | -45.14M | -37.61M | -31.54M |
| Operating CF Margin % | -0.92% | -0.64% | -0.94% | -0.86% | -0.84% | -0.55% | -0.38% |
| Operating CF Growth % | - | -0.13% | -0.48% | -0.35% | -0.09% | 0.17% | 0.16% |
| Net Income | -18.48M | -20.7M | -32.23M | -48.66M | -58.92M | -60.84M | -56.39M |
| Depreciation & Amortization | 270K | 365K | 483K | 3.16M | 4M | 1.55M | 1.49M |
| Stock-Based Compensation | 366K | 364K | 3.2M | 0 | 0 | 22.1M | 22.95M |
| Deferred Taxes | 936K | 746K | 0 | -6K | 49K | 0 | 0 |
| Other Non-Cash Items | 36K | 864K | 2.71M | 11.92M | 16.8M | 2.14M | 2.11M |
| Working Capital Changes | -1.52M | -2.4M | -4.79M | -7.84M | -7.06M | -2.56M | -1.7M |
| Change in Receivables | -262K | -2.52M | 1.46M | -2.43M | -2.19M | -3.1M | -1.31M |
| Change in Inventory | -1.25M | -2.61M | -5.05M | -6.46M | -3.64M | 918K | -229K |
| Change in Payables | -648K | 524K | 592K | 87K | 247K | -345K | 2.28M |
| Cash from Investing | 200K | -14.23M | 12.69M | -46.26M | -4.22M | -2.01M | 17.48M |
| Capital Expenditures | -316K | -720K | -911K | -3.67M | -1.32M | -807K | -1.45M |
| CapEx % of Revenue | 0.02% | 0.02% | 0.03% | 0.08% | 0.02% | 0.01% | 0.02% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 16K | -13.51M | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 12.11M | 45.62M | 234.83M | 4.5M | 2.47M | 21.4M | 1.36M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 114K | -52K | 446K | 0 | 0 | 1.49M | 1.46M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -18.71M | -21.48M | -31.54M | -45.1M | -46.45M | -38.42M | -32.98M |
| FCF Margin % | -0.94% | -0.66% | -0.96% | -0.93% | -0.87% | -0.56% | -0.39% |
| FCF Growth % | - | -0.15% | -0.47% | -0.43% | -0.03% | 0.17% | 0.14% |
| FCF per Share | -0.90 | -0.61 | -0.88 | -1.25 | -1.25 | -1.01 | -0.84 |
| FCF Conversion (FCF/Net Income) | 1.00x | 1.00x | 0.95x | 0.85x | 0.77x | 0.62x | 0.56x |
| Interest Paid | 1.36M | 1.4M | 3.06M | 0 | 0 | 2.98M | 3.48M |
| Taxes Paid | 226K | 196K | 259K | 0 | 0 | 471K | 556K |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -166.33% | -23.21% | -33.94% | -44.68% | -55.25% |
| Return on Invested Capital (ROIC) | - | -53.5% | -104.13% | -76.47% | -59.47% | -60.77% | -58.66% |
| Gross Margin | 61.42% | 68.77% | 64.77% | 73.59% | 74.29% | 73.9% | 74% |
| Net Margin | -92.38% | -63.52% | -98.47% | -100.51% | -109.8% | -88.6% | -67.3% |
| Debt / Equity | - | - | 0.12x | 0.14x | 0.16x | 0.35x | 0.66x |
| Interest Coverage | -5.97x | -7.70x | -10.16x | -57.06x | -55.01x | -19.16x | -16.45x |
| FCF Conversion | 1.00x | 1.00x | 0.95x | 0.85x | 0.77x | 0.62x | 0.56x |
| Revenue Growth | - | 62.94% | 0.42% | 47.91% | 10.84% | 27.98% | 22.01% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| UNITED STATES | 16.19M | 24.99M | 32.49M | 45.92M | 56.47M |
| UNITED STATES Growth | - | 54.37% | 29.99% | 41.34% | 22.97% |
| EMEA | 13.81M | 19.88M | 18.15M | 19.34M | 22.33M |
| EMEA Growth | - | 44.00% | -8.70% | 6.51% | 15.48% |
| Asia Pacific | 2.69M | 3.41M | 2.87M | 3.02M | 4.44M |
| Asia Pacific Growth | - | 27.06% | -16.05% | 5.48% | 46.84% |
| Other International Geographical Areas | 49K | 128K | 155K | 399K | 556K |
| Other International Geographical Areas Growth | - | 161.22% | 21.09% | 157.42% | 39.35% |
Pulmonx Corporation (LUNG) reported $91.7M in revenue for fiscal year 2024. This represents a 358% increase from $20.0M in 2018.
Pulmonx Corporation (LUNG) grew revenue by 22.0% over the past year. This is strong growth.
Pulmonx Corporation (LUNG) reported a net loss of $56.8M for fiscal year 2024.
Pulmonx Corporation (LUNG) has a return on equity (ROE) of -55.3%. Negative ROE indicates the company is unprofitable.
Pulmonx Corporation (LUNG) had negative free cash flow of $32.6M in fiscal year 2024, likely due to heavy capital investments.